Biocon inks settlement, license pact with  Amgen to market 2 biosimilars in US

Biocon Gains Over 1% as Subsidiary Signs Settlement and License Deal with Amgen

Mumbai (Udaipur Kiran News): Shares of Biocon Ltd rose over 1.6% in Wednesday’s trading session after its subsidiary, Biocon Biologics, signed a settlement and license agreement with Amgen Inc. paving the way for the commercial launch of its biosimilar drugs Bosaya (denosumab-kyqq) and Aukelso (denosumab-kyqq) in the United States. The stock was trading at ₹346.35, up ₹5.50 or 1.61%, compared to its previous close of ₹340.85 on the BSE. The scri…

Biocon inks settlement, license pact with  Amgen to market 2 biosimilars in US

NEW DELHI, Oct 1: Biotechnology firm Biocon on Wednesday said its unit has inked a settlement and license agreement with Amgen Inc., paving the way for commercialisation of two biosimilars used in the treatment of osteoporosis and cancer-related bone conditions.   Biocon Biologics has inked the pact with Amgen Inc for the commercialisation of Bosaya (denosumab-kyqq) and Aukelso (denosumab-kyqq) in the US, the company said in a regulatory filing.…